SCHEMBL2118542

SCHEMBL2118542

Cc1ccc(-n2cccc2)cc1NS(=O)(=O)c1ccc(O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
POLB P06746 1/20 0.52
HSD17B10 Q99714 1/20 0.52
ALDH1A1 P00352 7/20 0.47
GAA P10253 2/20 0.47
GFER P55789 2/20 0.47
GHSR Q92847 3/20 0.46
PKM P14618 3/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 1/20 0.46
BLM P54132 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C9 P11712 2/20 0.45
LMNA P02545 2/20 0.44
HTT P42858 1/20 0.44
CYTH2 Q99418 2/20 0.43
TSHR P16473 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120261 0.87 KMT2A (0.52) MEN1KMT2APOLBHSD17B10ALDH1A1
SCHEMBL2120628 0.87 ALDH1A1 (0.59) MEN1KMT2APOLBHSD17B10ALDH1A1
SCHEMBL2118397 0.85 ALDH1A1 (0.45) MEN1KMT2APOLBHSD17B10ALDH1A1
SCHEMBL2119976 0.81 KMT2A (0.45) MEN1KMT2APOLBHSD17B10ALDH1A1
SCHEMBL2119501 0.81 KMT2A (0.48) MEN1KMT2APOLBHSD17B10ALDH1A1
SCHEMBL2117940 0.80 KAT6A (0.47) MEN1KMT2APOLBHSD17B10ALDH1A1
SCHEMBL2117278 0.80 KMT2A (0.46) MEN1KMT2APOLBHSD17B10ALDH1A1
SCHEMBL2121533 0.78 MEN1 (0.45) MEN1KMT2APOLBHSD17B10ALDH1A1
SCHEMBL2119327 0.77 MEN1 (0.46) MEN1KMT2APOLBHSD17B10ALDH1A1
SCHEMBL2119238 0.75 CCR2 (0.46) MEN1KMT2APOLBHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 MEN1 3114/4885KMT2A 276/4885POLB 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.